Health and Healthcare

All Health and Healthcare Articles

Newest first · Page 365

Telik Surges on Trial Hold Release (TELK)

Telik, Inc. (NASDAQ:TELK) is seeing shares surging pre-market after it announced that the U.S. Food and Drug Administration has removed the partial hold on TELCYTA clinical trials after a complete review of TELCYTA data…

Douglas A. McIntyre · 19 years ago

Pfizer’s Dump Internet Program

Pfizer (PFE) is hooking up with doctor social network Sermo. According to The Wall Street Journal: "Pfizer-affiliated doctors will be able to talk candidly with the site’s 31,000 members, potentially giving the company insights…

Douglas A. McIntyre · 19 years ago

A Death Notice From Medtronic (MDT)

Medtronic (MDT) is warning doctors and patients to look at the company’s latest "defibrillator models because it was prone to a defect that has caused malfunctions in hundreds of patients and may have contributed…

Douglas A. McIntyre · 19 years ago

Biogen Idec (BIIB) Puts Itself On The Block

Biotech firm Biogen Idec (BIIB) has put itself on the block, another victim of shareholder activist by Carl Icahn. The company said that several firms had expressed interest. According to The Wall Street Journal,…

Douglas A. McIntyre · 19 years ago

Dendreon Has $130 Million More At Its Disposal, If It Wants (DNDN)

Dendreon Corporation (NASDAQ:DNDN) has secured a committed equity financing facility under which it may sell up to $130 million of its registered common stock to Azimuth Opportunity, Ltd. over an 18-month period. Dendreon is…

Douglas A. McIntyre · 19 years ago

Amgen: 24/7 & Business Week Compare & Contrast (AMGN, BIIB)

It seems that the thoughts of 24/7 Wall St. aren’t alone in the opinion of Amgen’s (NASDAQ:AMGN) future.  In this morning’s issue of Business Week’s "Inside Wall Street" segment, George Putnam of "The Turnaround…

Douglas A. McIntyre · 19 years ago

As Stent Business Falls Apart, Field Gets More Crowded

Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns about whether the product has long-term risks or whether it is more effective than…

Douglas A. McIntyre · 19 years ago

Invitrogen’s Broader Stem Cell Monitor Kit (IVGN)

Invitrogen Corp. (NASDAQ:IVGN) has announced the launch of a new kit that allows researchers to quickly and reliably monitor the state of human embryonic stem cells. The STEMPRO® EZChek™ Multiplex PCR Kit allows scientists…

Douglas A. McIntyre · 19 years ago

Noven Fails Phase III Lithium Study (NOVN)

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that a Phase 3 clinical study of its developmental once-daily lithium carbonate product did not meet its primary endpoint with statistical significance (p-value ≤ 0.15) in the treatment…

Douglas A. McIntyre · 19 years ago

Medtronic (MDT): The Stent Business Gets Worse

Medtronic (MDT) has decided to get into the stent business, making the little mesh tubes that keep arteries open. It is a perverse selection because Boston Scientific (BSX) and Johnson & Johnson (JNJ) has…

Douglas A. McIntyre · 19 years ago

Pfizer (PFE) Finally Gets The Message

For Pfizer, it has been a long and painful fall. In early 2004, its shares were just below $39. It was the age of Big Pharma. Most of the big drugs had not gone…

Douglas A. McIntyre · 19 years ago

Penwest Pharmaceuticals (PPCO) Set For Huge Fall

According to The Associated Press Endo Pharmaceuticals (ENDP). and Penwest Pharmaceuticals (PPCO). said Wednesday the patent on their pain drug Opana ER is being challenged by Impax Laboratories Inc. Endo and Penwest are currently…

Douglas A. McIntyre · 19 years ago

Hollis-Eden Pharmaceuticals (HEPH) Up 40%

Hollis-Eden (HEPH) and company in the development of a new class of small molecule compounds based on endogenous steroid hormones, today announced new preclinical data with its drug candidate HE3235 for the treatment of…

Douglas A. McIntyre · 19 years ago

For Boston Scientific (BSX) Stent News Gets More Complex

Stent sales for Boston Scientific (BSX) and Johnson & Johnson (JNJ) have taken a big drop since research began to emerge that the products could cause heart problems. There have been several conflicting studies…

Douglas A. McIntyre · 19 years ago